Transgene appoints Nathalie Adda as chief medical officer

pharmafile | September 21, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Nathalie Adda, Transgene 

Transgene has announced the appointment of Dr Nathalie Adda as chief medical officer.

Responsible for medical and regulatory affairs of the Company, Adda will be a member of its executive committee.

Adda is a medical doctor and a graduate of the Faculty of Medicine of the University of Paris VII where she specialised in infectious diseases. She also has a Master degree in bio-statistics and over 15 years’ experience in the pharma industry, in the US, working in the clinical development of products from early phase to market launch.

Since 2006 Adda held the position of senior medical director at Vertex Pharmaceuticals in Cambridge, MA, US, where she was responsible for the clinical development of Telaprevir, a drug approved in 2011, in the US and Europe, for the treatment of chronic hepatitis C.

Before her time at Vertex, Adda held similiar roles as associate director, Clinical Development at Gilead, as well as at Triangle Pharmaceuticals and Boehringer Ingelheim.

Dr Jean-Marc Limacher, director, Clinical Development and Catherine Mathis, director, Regulatory Affairs, will report to Adda.

“The addition of Nathalie Adda and the experience she brings represent a valuable asset for Transgene as the Company enters the early planning for its pivotal studies,” stated Philippe Archinard, chairman and chief executive of Transgene.

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its …


Transgene terminates oncolytic IO combo trial in advanced liver cancer

Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of …

Latest content